AKT1 and neoplasm: Mutations in the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway are frequent across EC molecular subgroups.71 In pre-clinical models, treatment with a PARPi resulted in increased expression of PI3K/Akt/mTOR pathway members across various tumor models.72,73 Furthermore, blocking the PI3K/Akt/mTOR pathway resulted in reduced HRR by suppressing BRCA1/2 expression enhancing sensitivity to PARPi.74 These pre-clinical data led to a multi-disease site clinical trial64 combining olaparib with the AKT inhibitor capivasertib.